Nephron Diuretics, Dyslipidemia Pharmacology, Ophthalmic Glaucoma Drops & Dermatologic Retinoids

Mannitol is a pharmacologically inert, non-reabsorbable 6-carbon sugar alcohol administered intravenously that is freely filtered at the glomerulus (except in anuria) and undergoes zero tubular reabsorption along the Proximal Convoluted Tubule and Thin Descending Limb of the Loop of Henle. By exerting high intraluminal osmotic pressure, mannitol retains water inside the renal tubule and washes out the medullary interstitial osmotic gradient, inhibiting passive water reabsorption and secondarily increasing urinary Na+ and Cl- excretion. Clinically, intravenous mannitol is a first-line emergency therapy to draw free water out of brain parenchyma or the ocular vitreous body in acute intracranial hypertension / impending cerebral herniation (elevated ICP) and acute severe intraocular pressure (IOP) crises, as well as to promote tubular flushing in early myoglobinuric rhabdomyolysis or tumor lysis syndrome.

High-yield NBOME/USMLE board trap—Why Mannitol is STRICTLY CONTRAINDICATED in Decompensated Heart Failure, Pulmonary Edema, and Anuric Renal Failure: Immediately after IV infusion—before mannitol is filtered into the urine—mannitol resides in the intravascular plasma space and increases plasma osmolality. This osmotic gradient pulls massive volumes of intracellular and interstitial water INTO the intravascular extracellular fluid (ECF) compartment! If the patient has decompensated congestive heart failure (CHF) or anuric acute kidney injury (where mannitol cannot be excreted into the urine), this acute intravascular volume expansion overwhelms the left ventricle, precipitating fulminant, life-threatening Flash Pulmonary Edema alongside severe dilutional hyponatremia (as free water shifts out of cells into plasma)! Later, if massive mannitol diuresis occurs without water replacement, loss of hypotonic urine (water in excess of sodium) causes dehydration and hypernatremia.

Loop Diuretics—comprising the sulfonamide derivatives Furosemide, Bumetanide (40× more potent than furosemide), and Torsemide (high oral bioavailability in right-sided heart failure gut edema), plus the non-sulfonamide phenoxyacetic acid derivative Ethacrynic Acid—inhibit the luminal Na+/K+/2Cl- cotransporter (NKCC2) in the Thick Ascending Limb (TAL) of the Loop of Henle (the exact transporter mutated in autosomal recessive Bartter Syndrome!). Because the TAL reabsorbs 20–25% of filtered Na+ and generates the hypertonic medullary interstitium required for ADH-mediated water concentration, loop diuretics are the most efficacious (highest Emax) diuretics available—serving as first-line therapy for acute cardiogenic pulmonary edema, decompensated heart failure, cirrhotic ascites, nephrotic edema, hypertension in severe CKD (eGFR <30 mL/min, where thiazides lose efficacy), and acute severe Hypercalcemia.

Crucial cellular physiology on boards—Why "Loops Lose Calcium" (and Magnesium): Normally, in the Thick Ascending Limb, NKCC2 pumps Na+, K+, and 2Cl- into the cell, and luminal ROMK channels recycle K+ back into the urine lumen. This K+ recycling creates a +8 to +10 mV lumen-positive transepithelial electrical potential that electrostatically repels divalent cations (Ca2+ and Mg2+), driving their paracellular reabsorption between TAL tight junctions (via claudin-16/19) into the blood. When Furosemide blocks NKCC2, K+ recycling stops, the lumen-positive electrical potential collapses to zero, and paracellular reabsorption of Ca2+ and Mg2+ ceases—causing marked hypercalciuria and hypomagnesemia! Furthermore, loop diuretics stimulate renal COX-2 synthesis of vasodilatory prostaglandins (PGE2 and PGI2) that dilate the afferent arteriole (co-administering NSAIDs/indomethacin blocks this prostaglandin synthesis and blunts loop diuretic efficacy!). Signature loop toxicities: (1) Hypokalemic, Hypochloremic Metabolic Alkalosis (contraction + aldosterone + distal Na+ delivery); (2) Dose-related reversible or permanent Sensorineural Ototoxicity (via inhibition of stria vascularis NKCC1 in the inner ear—highest risk with Ethacrynic Acid or when combined with aminoglycosides!); (3) Hyperuricemia / Gout (competes with urate for proximal OAT secretion); and (4) Sulfa allergy with furosemide/bumetanide/torsemide (Ethacrynic Acid contains NO sulfonamide moiety and is the classic board answer for a patient with severe anaphylactic sulfa allergy requiring a loop diuretic—though ethacrynic acid has the highest ototoxicity and GI bleeding risk!).

Signature Thiazide Toxicities (Mnemonic: HyperGLUC + Hyponatremia/Hypokalemic Alkalosis): Like loop diuretics, thiazides increase Na+ and fluid delivery to the cortical collecting tubule, stimulating principal-cell ENaC Na+ uptake and K+/H+ excretion to cause Hypokalemic, Hypochloremic Metabolic Alkalosis. In addition, because thiazides impair only the cortical diluting segment (DCT) while leaving the medullary concentrating gradient intact, patients continue to secrete ADH and cannot excrete free water—making thiazides the #1 drug class causing severe, symptomatic Hyponatremia in elderly patients! The four 'HyperGLUC' metabolic abnormalities of thiazides are: (1) HyperGlycemia (hypokalemia hyperpolarizes pancreatic beta-cells, impairing K_ATP channel closure and insulin exocytosis); (2) HyperLipidemia (↑ total cholesterol, LDL, and triglycerides); (3) HyperUricemia / acute gout flares (competes for proximal OAT urate secretion); and (4) HyperCalcemia (unmasks subclinical primary hyperparathyroidism!).

Cortical Collecting Tubule (CCT) Potassium-Sparing Diuretics: Act on principal cells (where 2–5% of Na+ is reabsorbed via Epithelial Sodium Channels [ENaC], creating a lumen-negative potential that drives K+ excretion via ROMK and H+ secretion by alpha-intercalated cells). Blocking this pathway causes Hyperkalemia and a Normal-Anion-Gap Metabolic Acidosis (Type 4 Renal Tubular Acidosis!) via two distinct mechanisms:

1. Mineralocorticoid Receptor (MR) Antagonists: Spironolactone, Eplerenone, and Finerenone. Competitively block cytosolic aldosterone (mineralocorticoid) receptors inside principal and intercalated cells, downregulating synthesis of ENaC channels, basolateral Na+/K+-ATPase pumps, and H+-ATPase pumps.Proven to reduce mortality and myocardial fibrosis in Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF ≤35%), primary hyperaldosteronism (Conn syndrome), and cirrhotic ascites (where spironolactone is paired with furosemide in a 100 mg : 40 mg ratio). Crucial endocrine board distinction: Spironolactone is non-selective and cross-blocks androgen receptors (AR) and progesterone receptors—causing painful gynecomastia, mastodynia, erectile dysfunction, decreased libido, and menstrual irregularities (which makes spironolactone therapeutically useful for PCOS hirsutism and female hormonal acne!). By contrast, Eplerenone (and the non-steroidal MR antagonist Finerenone, which reduces CKD progression in Type 2 Diabetes) is highly selective for the mineralocorticoid receptor and causes ZERO gynecomastia or antiandrogen side effects!

2. Direct Luminal ENaC Channel Blockers: Amiloride and Triamterene. Directly plug the luminal pore of ENaC on principal cells independently of aldosterone. Amiloride is the specific board drug of choice for two classic conditions: (a) Lithium-Induced Nephrogenic Diabetes Insipidus (because lithium enters collecting duct principal cells specifically through luminal ENaC channels to inhibit glycogen synthase kinase-3 and downregulate Aquaporin-2; blocking ENaC with amiloride prevents lithium entry into the cell without lowering serum therapeutic lithium levels!); and (b) Liddle Syndrome (autosomal dominant gain-of-function mutation in ENaC causing hypertension, hypokalemic alkalosis, and low renin/low aldosterone).

• Vasopressin V2 Receptor Antagonists ('Vaptans' / Aquaretics: Tolvaptan [oral], Conivaptan [IV]): Competitively block basolateral Gs-coupled V2 receptors on medullary collecting duct principal cells (conivaptan blocks both V1a and V2 receptors), preventing cAMP/PKA-mediated insertion of Aquaporin-2 (AQP2) water channels into the apical membrane. Unlike classical saluretic diuretics (which excrete NaCl + water), vaptans induce pure aquaresis (electrolyte-free water excretion), decreasing urine osmolality and raising serum [Na+]. Indicated for euvolemic (SIADH) or hypervolemic (CHF) hyponatremia and to slow cyst growth in Autosomal Dominant Polycystic Kidney Disease (ADPKD—where cAMP drives renal tubular cyst proliferation!). High-yield boxed warnings for Tolvaptan: (1) Rapid overcorrection of chronic hyponatremia (>8–10 mEq/L in 24 hours) precipitates catastrophic Osmotic Demyelination Syndrome (Central Pontine Myelinolysis—locked-in quadriplegia!); and (2) Idiosyncratic Hepatotoxicity (never use for >30 days in SIADH or in patients with underlying cirrhosis!).

• SGLT2 Inhibitors ('-flozins': Empagliflozin, Dapagliflozin, Canagliflozin, Sotagliflozin): Inhibit the Sodium-Glucose Cotransporter-2 (SGLT2) in the S1/S2 segments of the Proximal Convoluted Tubule (PCT), blocking reabsorption of ~90% of filtered glucose and coupled Na+. By restoring distal NaCl delivery to the macula densa, SGLT2 inhibitors restore tubuloglomerular feedback—triggering adenosine-mediated afferent arteriolar vasoconstriction that lowers intraglomerular hyperfiltration pressure! Consequently, empagliflozin and dapagliflozin are cornerstone disease-modifying agents that reduce cardiovascular death/hospitalization across ALL Heart Failure phenotypes (HFrEF and HFpEF!) and slow progression of Diabetic and Non-Diabetic Proteinuric Chronic Kidney Disease—even in patients WITHOUT diabetes! Signature SGLT2i toxicities: vulvovaginal candidiasis / balanitis (glucosuria feeds Candida), UTIs, Fournier gangrene, volume depletion, and Euglycemic Diabetic Ketoacidosis (DKA with blood glucose <200–250 mg/dL, triggered by surgical stress/fasting—hold SGLT2 inhibitors 3–4 days before scheduled surgery!).

When maximally tolerated high-intensity statin therapy fails to achieve the target LDL-C reduction (e.g., LDL-C ≥55–70 mg/dL in very-high-risk ASCVD or Familial Hypercholesterolemia) or in complete statin intolerance, non-statin LDL-lowering agents are added sequentially:

1. Ezetimibe (First-Line Non-Statin Add-On): Selectively localizes to the brush border of small-intestinal jejunal enterocytes and inhibits the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1), blocking dietary and biliary cholesterol absorption from the gut lumen without affecting fat-soluble vitamin absorption. Decreasing chylomicron cholesterol delivery to the liver upregulates hepatic LDL receptors, lowering LDL-C by an additional 18% to 25% with minimal toxicity (rare mild LFT elevation or diarrhea).

2. PCSK9 Inhibitors (Monoclonal Antibodies: Evolocumab, Alirocumab; Small-Interfering RNA [siRNA]: Inclisiran): Normally, after a hepatocyte surface LDL receptor binds an LDL particle and internalizes via clathrin-coated pits into an endosome, the LDL receptor separates from LDL and recycles back to the hepatocyte surface up to 150 times. However, secreted PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) binds the extracellular EGF-A domain of the LDL receptor and targets the entire LDLR complex for lysosomal degradation! Subcutaneous Evolocumab and Alirocumab (every 2–4 weeks) bind circulating PCSK9 protein—and Inclisiran (every 6 months, conjugated to GalNAc for hepatocyte ASGPR uptake) degrades hepatic PCSK9 mRNA via the RISC complex—preventing LDLR degradation, massively increasing hepatocyte surface LDL receptor density, and slashing LDL-C by 50% to 65% (plus lowering Lipoprotein(a) [Lp(a)] by ~25%!).

3. Bempedoic Acid (ATP-Citrate Lyase Inhibitor): Inhibits ATP-citrate lyase (ACL) two steps upstream of HMG-CoA reductase in the cholesterol synthesis pathway. Why does bempedoic acid cause ZERO myopathy or rhabdomyolysis in statin-intolerant patients? Because bempedoic acid is an inactive prodrug activated exclusively by Very-Long-Chain Acyl-CoA Synthetase-1 (ACSVL1)—an enzyme expressed in hepatocytes but completely ABSENT in skeletal muscle cells! (Signature toxicities: hyperuricemia/gout and tendon rupture).

4. Bile Acid Sequestrants / Resins (Cholestyramine, Colestipol, Colesevelam): Positively charged non-absorbable anion-exchange polymers that bind negatively charged bile acids in the intestinal lumen, preventing their ileal enterohepatic reabsorption and forcing the liver to divert hepatic cholesterol into de novo bile acid synthesis via 7α-hydroxylase. Also used for pruritus of cholestasis/PBC, bile acid diarrhea (post-cholecystectomy/ileal Crohn resection), and digitalis/leflunomide washout. Two high-yield board traps: (a) Bile acid resins INCREASE serum Triglycerides (VLDL) and are contraindicated in hypertriglyceridemia (>300–400 mg/dL); and (b) They deplete the bile acid pool, causing supersaturated lithogenic bile and cholesterol gallstones, while binding fat-soluble vitamins (A, D, E, K) and oral drugs (warfarin, digoxin, levothyroxine, thiazides) in the gut!

• Fibrates (Fenofibrate, Gemfibrozil, Bezafibrate): Ligands that bind and activate the nuclear transcription factor Peroxisome Proliferator-Activated Receptor-Alpha (PPAR-α) in hepatocytes and adipose/skeletal muscle endothelium. Activating PPAR-α upregulates transcription of Lipoprotein Lipase (LPL) and ApoA-I / ApoA-II while downregulating ApoC-III (an endogenous inhibitor of LPL) and hepatic VLDL synthesis. Consequently, fibrates are the #1 most effective drugs for lowering severe Hypertriglyceridemia (↓ TG by 35% to 50%—preventing acute hypertriglyceridemic pancreatitis when fasting TG ≥500–1,000 mg/dL!) while modestly raising HDL-C. High-yield Fibrate toxicities: (1) Cholesterol Gallstones (cholelithiasis)—because fibrates inhibit hepatic cholesterol 7α-hydroxylase (decreasing bile acid synthesis) and increase biliary cholesterol secretion via ABCG5/G8, supersaturating bile with cholesterol!; and (2) Myositis / Rhabdomyolysis when combined with statins (always prefer Fenofibrate over Gemfibrozil if a statin must be co-administered, because gemfibrozil potently inhibits statin glucuronidation and OATP1B1!). Note that Fenofibrate also reversibly increases serum creatinine by ~0.1–0.2 mg/dL.

• Omega-3 Fatty Acids & Icosapent Ethyl (Purified EPA Ethyl Ester): High-dose (4 g/day) Icosapent Ethyl (pure eicosapentaenoic acid [EPA], without DHA) activates hepatic beta-oxidation and inhibits diacylglycerol acyltransferase (DGAT) to reduce VLDL-TG synthesis (↓ TG by 20–30%) and is FDA-approved to significantly reduce cardiovascular mortality, MI, and stroke (REDUCE-IT trial) in statin-treated patients with persistently elevated triglycerides (135–499 mg/dL) (risks: mild increase in atrial fibrillation and bleeding).

• Niacin (Vitamin B3 / Nicotinic Acid): Binds Gi-coupled GPR109A receptors on adipocytes to inhibit hormone-sensitive lipase (HSL), reducing free fatty acid flux to the liver and decreasing hepatic VLDL/LDL synthesis while inhibiting hepatic HDL catabolism—making niacin the most potent pharmacological agent for raising HDL-C (↑ 15% to 35%), though clinical trials showed no incremental mortality benefit when added to statins. Classic board toxicities of Niacin: (1) Intense Cutaneous Facial Flushing and Pruritus—mediated by dermal Langerhans cell release of Prostaglandin D2 (PGD2) and PGE2 (NOT histamine!), which is prevented by pre-treatment with Aspirin (325 mg) or NSAIDs 30 minutes prior!; (2) Hyperuricemia and acute Gout flares; and (3) Hyperglycemia / insulin resistance and hepatotoxicity.

Remember that topical ophthalmic drops drain through the nasolacrimal duct directly into the highly vascularized nasal mucosa—bypassing first-pass hepatic metabolism and entering the systemic circulation like an intravenous dose (patients should perform punctal occlusion for 1–2 minutes after instillation!):

1. Topical Beta-Adrenergic Antagonists (Timolol, Carteolol, Levobunolol [non-selective β1/β2] vs. Betaxolol [β1-selective]): Block Gs-coupled β2/1-receptors on the ciliary epithelium, reducing intracellular cAMP and decreasing aqueous humor synthesis (with zero effect on pupil size or accommodation). High-yield board trap: Systemic absorption of non-selective Timolol through the nasolacrimal mucosa blocks bronchial β2-receptors and cardiac SA/AV nodal β1-receptors—precipitating life-threatening bronchospasm in Asthma/COPD, symptomatic bradycardia / third-degree AV heart block, and acute decompensated heart failure! (Cardioselective Betaxolol carries a lower risk of bronchospasm).

2. Topical Alpha-2-Adrenergic Agonists (Brimonidine, Apraclonidine): Activate Gi-coupled α2-receptors on the ciliary epithelium to decrease aqueous humor synthesis, while Brimonidine additionally exerts a dual mechanism by increasing uveoscleral outflow! Crucial pediatric board rule: Brimonidine is STRICTLY CONTRAINDICATED in infants and toddlers (<2 years old) because it crosses the immature blood-brain barrier to stimulate central medullary α2-receptors, causing profound CNS depression, lethargy, hypotension, bradycardia, coma, and life-threatening apnea! Local adverse effects include follicular allergic blepharoconjunctivitis and dry mouth; Apraclonidine is also used diagnostically to confirm Horner Syndrome (reverses ptosis and miosis in the denervated eye due to alpha-1 denervation supersensitivity!).

3. Topical Carbonic Anhydrase Inhibitors (Dorzolamide, Brinzolamide) & Systemic Acetazolamide/Methazolamide: Inhibit ciliary epithelium CA-II to decrease HCO3- and aqueous fluid secretion without systemic metabolic acidosis when applied topically (causes a bitter metallic taste in the throat as drops drain down the nasolacrimal duct; avoid in severe sulfonamide allergy or corneal endothelial dysfunction).

Acute Angle-Closure Glaucoma (AACG) Emergency Management: A hyperopic (farsighted) older patient or patient given an anticholinergic/alpha-1 sympathomimetic in a dark room develops sudden, excruciating unilateral ocular pain, frontal headache, nausea/vomiting, rainbow halos around lights, a rock-hard globe (IOP >40–60 mmHg), a steamy/cloudy cornea, conjunctival injection, and a mid-dilated (4–6 mm), fixed, non-reactive pupil. Before performing definitive bilateral laser peripheral iridotomy, immediate medical therapy combines: (1) Topical Pilocarpine (or Carbachol)—direct M3 muscarinic agonists (Gq) that contract the iris sphincter pupillae muscle (producing miosis) and contract the longitudinal fibers of the ciliary muscle, pulling the scleral spur to mechanically open the trabecular meshwork and canal of Schlemm so trapped aqueous humor can drain!; (2) Topical Timolol + Topical Brimonidine/Apraclonidine + IV Acetazolamide to immediately halt new aqueous humor production; and (3) IV Mannitol (osmotic diuretic) to rapidly shrink vitreous volume. (Also note the newer POAG class: Netarsudil, a Rho-kinase [ROCK] inhibitor that relaxes trabecular meshwork actin-myosin stress fibers to directly increase trabecular outflow, causing conjunctival hyperemia and corneal verticillata). Never give **atropine, tropicamide, phenylephrine, ipratropium mist into the eyes, or topiramate** to a patient with narrow angles, as mydriasis or ciliary body swelling crowds the iridocorneal angle and precipitates acute angle-closure glaucoma! (Note: Topiramate uniquely causes idiosyncratic ciliochoroidal effusion with anterior rotation of the lens-iris diaphragm, causing bilateral acute angle-closure glaucoma and acute myopia—treated by stopping topiramate and giving cycloplegics, NOT pilocarpine!).

Diagnostic Mydriasis vs. Cycloplegia Exam Discriminator: When an ophthalmologist needs to dilate the pupil (mydriasis) for a routine funduscopic retinal exam without paralyzing near-vision accommodation (cycloplegia), they instil the selective alpha-1 agonist Phenylephrine, which contracts the radial iris dilator muscle (innervated by sympathetic alpha-1 receptors) while sparing the ciliary muscle (innervated exclusively by parasympathetic M3 receptors!). Conversely, Muscarinic Antagonists (Tropicamide [shortest acting, 4–6h], Cyclopentolate [1 day], Homatropine, and Atropine [longest acting, 7–14 days]) block M3 receptors on BOTH the iris sphincter and ciliary muscle, producing BOTH Mydriasis AND Cycloplegia (required for accurate pediatric cycloplegic refraction or relieving painful ciliary spasm in anterior uveitis/iritis!).

For severe, recalcitrant, scarring Nodulocystic Acne (or acne conglobata) that fails oral antibiotics + topical retinoids/BPO, the definitive curative oral medication is Oral Isotretinoin (13-cis-retinoic acid), which induces sebaceous gland apoptosis and shrinks sebaceous gland volume by >80–90% over a 15-to-20-week course. Because oral isotretinoin is one of the most potent human teratogens known—disrupting HOX gene expression and cranial neural crest cell migration during weeks 3–8 of gestation to cause Retinoid Embryopathy (microtia/anotia [absent external ears], micrognathia, cleft palate, thymic aplasia/DiGeorge-like defect, conotruncal cardiac defects [transposition of the great vessels, tetralogy of Fallot], and hydrocephalus/cerebellar vermis agenesis)—every prescriber, pharmacy, and patient MUST comply with the FDA-mandated iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program:

• iPLEDGE Requirements for Patients Who Can Become Pregnant: Must commit to TWO simultaneous forms of effective contraception (1 primary + 1 secondary, or complete abstinence) starting at least 1 month BEFORE initiating isotretinoin, throughout the entire treatment course, and for 1 full month AFTER discontinuing isotretinoin; and must have TWO negative laboratory pregnancy tests (serum or urine β-hCG) before receiving the first prescription, followed by a negative pregnancy test EVERY single month before each 30-day supply is dispensed (and patients taking isotretinoin must NOT donate blood during therapy or for 1 month after stopping, lest transfused blood go to a pregnant recipient!). Note: Unlike isotretinoin (1-month post-treatment contraception), the oral second-generation retinoid Acitretin (used for severe pustular/erythrodermic psoriasis) is esterified in the presence of ethanol into etretinate (half-life >120 days in subcutaneous fat!) and requires strict contraception for 3 FULL YEARS after discontinuing acitretin!

• Signature Isotretinoin Toxicities & Drug Contraindications: (1) Mucocutaneous dryness (>90% of patients: cheilitis/chapped lips, xerosis, dry eyes, epistaxis, photosensitivity); (2) Hypertriglyceridemia (↑ VLDL/TG → risk of acute pancreatitis) and Hepatotoxicity (transaminitis)—always monitor baseline and serial fasting lipid panels and LFTs!; (3) Myalgias, arthralgias, premature epiphyseal closure, and night blindness; (4) Neuropsychiatric monitoring for depression/suicidality; and (5) ABSOLUTE CONTRAINDICATION with Tetracyclines (Doxycycline, Minocycline, Tetracycline) or Vitamin A supplements because combining isotretinoin with a tetracycline precipitates Idiopathic Intracranial Hypertension (Pseudotumor Cerebri: severe headache, pulsatile tinnitus, papilledema, abducens CN VI palsy, vision loss)! Always wash out oral doxycycline/minocycline before starting oral isotretinoin!

• Topical Corticosteroid Potency Classes (Class I Super-High Potency = Clobetasol propionate 0.05%, Halobetasol; Class III/IV Medium Potency = Triamcinolone acetonide 0.1%, Fluocinonide; Class VII Lowest Potency = Hydrocortisone 1%–2.5%): Induce annexin A1 (lipocortin-1) to inhibit phospholipase A2 and NF-κB. Crucial dermatologic anatomical rule: Percutaneous absorption is highest where the stratum corneum is thinnest (eyelids, face, neck, axillae, groin/genitalia, and intertriginous skin folds) and lowest on thick palms, soles, elbows, and knees. Applying super-high-potency Clobetasol to the face or intertriginous groin causes irreversible dermal atrophy (paper-thin skin, telangiectasias, purpura, striae), periorificial dermatitis, steroid rosacea, cataracts/glaucoma (around the eyes), and systemic HPA-axis adrenal suppression! Therefore, use only low-potency Hydrocortisone 1%–2.5% or steroid-sparing topical calcineurin inhibitors (Tacrolimus ointment / Pimecrolimus cream, or the topical PDE-4 inhibitor Crisaborole / topical JAK1/2 inhibitor Ruxolitinib cream, which cause ZERO skin atrophy!) on the face, eyelids, and skin folds!

• Plaque Psoriasis, Actinic Keratosis & Ectoparasite/Alopecia Pharmacology: First-line topical therapy for localized plaque psoriasis pairs a high-potency corticosteroid with Calcipotriene (Calcipotriol—a synthetic Vitamin D3 analog that binds nuclear Vitamin D Receptors [VDR] to inhibit keratinocyte proliferation and promote differentiation; high doses can cause hypercalcemia) or topical Tazarotene. For premalignant Actinic Keratoses and superficial Basal Cell Carcinoma (or genital warts), topical 5-Fluorouracil (5-FU) cream inhibits thymidylate synthase to selectively destroy rapidly dividing dysplastic keratinocytes, while topical Imiquimod acts as a Toll-Like Receptor 7 (TLR7) agonist that stimulates local dendritic cells to secrete IFN-α, TNF-α, and IL-12. For Scabies (Sarcoptes scabiei) and Pediculosis (head/pubic lice), first-line topical therapy is 5% Permethrin cream, a pyrethroid neurotoxin that blocks neuronal voltage-gated sodium (Na+) channel deactivation/inactivation, causing persistent depolarization and paralysis of the mite/louse (far safer than Lindane, which blocks GABA-A Cl- channels and causes neurotoxic seizures and aplastic anemia!). Finally, for Androgenetic Alopecia, topical/oral Minoxidil opens ATP-sensitive potassium (K_ATP) channels to hyperpolarize vascular smooth muscle, dilate scalp arterioles, and prolong the anagen (growth) phase of hair follicles, while oral Finasteride (1 mg) inhibits Type II 5α-reductase to block conversion of testosterone to dihydrotestosterone (DHT).

For Chronic Gout Prophylaxis (indicated for ≥2 flares/year, tophi, urate nephrolithiasis, or CKD stage ≥3, targeting a serum uric acid <6.0 mg/dL) and Tumor Lysis Syndrome, three mechanisms lower serum urate:

1. Xanthine Oxidase Inhibitors (Allopurinol [purine analog] & Febuxostat [non-purine]): Inhibit xanthine oxidase (XO), blocking the two-step oxidation of hypoxanthine → xanthine → uric acid (#1 first-line chronic urate-lowering class!). Crucial board traps: (a) Because Azathioprine and 6-Mercaptopurine (6-MP) are inactivated by xanthine oxidase, co-administering Allopurinol or Febuxostat with azathioprine/6-MP causes lethal pancytopenia!; (b) Allopurinol causes severe DRESS syndrome and Stevens-Johnson Syndrome / TEN (strongly associated with the HLA-B*58:01 allele in Han Chinese, Thai, Korean, and African American patients!); and (c) Febuxostat carries an FDA boxed warning for increased cardiovascular death compared with allopurinol.

2. Uricosuric Agents (Probenecid, plus the ARB Losartan and Fenofibrate): Probenecid inhibits the proximal convoluted tubule apical reabsorption transporter URAT1 (SLC22A12), increasing urinary uric acid excretion. Contraindicated in patients with uric acid kidney stones (nephrolithiasis) or eGFR <30–50 mL/min, and precipitates hemolysis in G6PD deficiency! (Note: Low-dose aspirin [<325 mg/day] inhibits tubular urate secretion and causes hyperuricemia, whereas only toxic high-dose aspirin [>3–4 g/day] is uricosuric!).

3. Recombinant Urate Oxidase / Uricase (Pegloticase [chronic refractory tophaceous gout] & Rasburicase [acute Tumor Lysis Syndrome]): Enzymatically oxidizes poorly soluble uric acid into highly water-soluble allantoin, which is rapidly excreted by the kidneys. Both drugs generate hydrogen peroxide (H2O2) as a reaction byproduct and are ABSOLUTELY CONTRAINDICATED in G6PD Deficiency (causes fulminant intravascular hemolytic anemia and methemoglobinemia!).

• Bisphosphonates (#1 First-Line for Postmenopausal, Male, and Glucocorticoid-Induced Osteoporosis, Paget Disease of Bone, and Malignant Hypercalcemia: Alendronate, Risedronate, Ibandronate [oral]; Zoledronic Acid, Pamidronate [IV]): Pyrophosphate analogs with a P-C-P backbone that avidly bind hydroxyapatite calcium crystals in bone matrix. When osteoclasts resorb bisphosphonate-coated bone, nitrogen-containing bisphosphonates internalize and inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, blocking prenylation of GTP-binding proteins, disrupting the osteoclast ruffled border, and inducing osteoclast apoptosis. Four classic board toxicities of Bisphosphonates: (1) Corrosive Pill Esophagitis and Esophageal Ulceration (patients MUST swallow oral alendronate on an empty stomach with 8 oz of plain water and remain strictly upright for ≥30–60 minutes! Contraindicated in achalasia, esophageal stricture, or inability to sit upright—use IV zoledronic acid instead!); (2) Osteonecrosis of the Jaw (ONJ—exposed necrotic mandibular/maxillary bone after a dental extraction in oncology patients on high-dose IV zoledronate or denosumab!); (3) Atypical Subtrochanteric Femoral Shaft Stress Fractures after >3–5 years of continuous suppression of bone turnover (requires a bisphosphonate 'drug holiday'!); and (4) Hypocalcemia and acute nephrotoxicity (contraindicated if CrCl <30–35 mL/min; use Denosumab in severe CKD!).

• Parathyroid Hormone Analogs (Teriparatide [recombinant PTH 1–34] & Abaloparatide [PTHrP analog]): Whereas continuous endogenous PTH elevation (primary hyperparathyroidism) stimulates osteoblast RANKL expression to cause net bone resorption, once-daily intermittent subcutaneous pulses of Teriparatide or Abaloparatide selectively stimulate osteoblast survival and osteoblastic bone formation (anabolic bone builders!). Used for severe osteoporosis with fragility fractures (historically carried an osteosarcoma warning in rats—contraindicated in patients with Paget disease of bone, prior skeletal radiation, unexplained elevated alkaline phosphatase, or open pediatric epiphyses!).